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Introduction
A new era of cancer research is underway with the realization 
that the initiation and regulation of cancer involves more than 
the identification of oncogenes or tumor suppressor genes. The 
field of epigenetics has exploded in recent years with multiple 
studies demonstrating the involvement of DNA methylation and 
chromatin modification in cancer development. Both mecha-
nisms regulate gene transcription by controlling the access of 
transcription factors to DNA. Chromatin disorders have been 
implicated in the devastating effects of solid tumors as well as 
myeloid leukemia, Rubinstein-Taybi Syndrome and malignant 
rhabdoid tumors.1,2
The proper functioning of the SWI/SNF chromatin remodel-
ing complex is vital to appropriate cell cycle control and tumor 
suppression. Despite the seemingly small (5%) amount of genes 
whose regulation the complex affects, they are widely dispersed 
throughout the genome with more repression than activation.3 
The ubiquitously expressed multi-unit complex is composed 
of a small core including BRG1 or BRM, SNF5/INI1/BAF47, 
Recent studies have established that two core members of the SWI/SNF chromatin remodeling complex, BRG1 and SNF5/
INI1, possess tumor-suppressor activity in human and mouse cancers. While the third core member, BAF155, has been 
implicated by several studies as having a potential role in tumor development, direct evidence for its tumor suppressor 
activity has remained lacking. Therefore, we screened for BAF155 deficiency in a large number of human tumor cell lines. 
We identified two cell lines, the SNUC2B colon carcinoma and the SKOV3 ovarian carcinoma, displaying a complete loss 
of protein expression while maintaining normal levels of mRNA expression. The SKOV3 cell line possesses a heterozygous 
4 bp deletion that results in an 855AA truncated protein, while the cause of the loss of BAF155 expression in the SNUC2B 
cell line appears due to a post-transcriptional error. However, the lack of detectable BAF155 expression did not affect 
sensitivity to RB-mediated cell cycle arrest. Re-expression of full length but not a truncated form of BAF155 in the two 
cancer cell lines leads to reduced colony forming ability characterized by replicative senescence but not apoptosis. 
Collectively, these data suggest that loss of BAF155 expression represents another mechanism for inactivation of SWI/SNF 
complex activity in the development in human cancer. Our results further indicate that the c-terminus proline-glutamine 
rich domain plays a critical role in the tumor suppressor activity of this protein.
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BAF155, BAF170 and variable associated complex members 
depending on cell type and stage of development. Most core 
members are vital to life and essential to development as homo-
zygous knockout mice show embryonic lethality.3-8
Either BRG1 or BRM serve as the catalytic subunit of the 
complex. Approximately ten percent of human cancer cell lines 
show mutations or deletions of these genes.2 Another core mem-
ber, SNF5/BAF47/INI1, is an established tumor suppressor gene 
that is deleted in almost all malignant rhabdoid tumors.9 The 
absence of SNF5 protein provides the diagnostic marker for these 
cancers. Genetically engineered mice also provide evidence for 
the tumor suppressor activity of these genes. Mice heterozygous 
for Brg1 develop tumors resembling breast adenocarcinomas,4,10 
while heterozygous SNF5 mice develop rhabdoid tumors histo-
logically similar to their human counterparts.5,7,8 Several stud-
ies have implicated that the SWI/SNF complex acts as a tumor 
suppressor via its role in cell cycle regulation. The SWI/SNF 
complex can control cellular proliferation by its association with 
known cell cycle checkpoint genes, such as BRCA1, cyclin E, 
p21, p53 and p16.11-17
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in a human cell line with endogenous expression had no little or 
no effect on cell growth. Furthermore, truncation of the c-termi-
nus of BAF155 caused a significant loss of its tumor suppression 
activity. Our results establish another member of the SWI/SNF 
complex as a tumor suppressor gene that may contribute to its 
regulation of the cell cycle and cellular senescence.
Results
Loss of BAF155 expression in two carcinoma cell lines. To 
gauge the frequency of BAF155 loss as well as to generate a cell 
culture model system to study BAF155 functions, we screened 
>100 human cancer cell lines by protein gel blot for BAF155 
expression. We identified two carcinoma cell lines lacking 
BAF155 protein (Fig. 1A): SKOV3, an ovarian carcinoma cell 
line, and SNUC2B, a colorectal carcinoma cell line. Initial 
screening of nuclear extracts from these cells showed that other 
complex members, including BRG1 and SNF5, were present. We 
also screened whole cell extracts to determine whether BAF155 
still appeared in the cytoplasm. We could not observe BAF155 
expression under any protein extraction conditions in these two 
carcinoma cell lines. Both cell lines contained a full complement 
of all other SWI/SNF complex members, although SNUC2B’s 
BRG1 ATPase domain has two point mutations.26 However, as 
The unique contribution of BAF155, another core member, to 
the complex remains ill-defined. Initially isolated as a gene highly 
expressed in thymus/low in periphery, BAF155 actually shows 
ubiquitous expression similar to the rest of the SWI/SNF com-
plex. Also known as SWI3 in yeast, SRG3 (SWI3 related gene) in 
mouse, and MOIRA in Drosophila, BAF155 has been implicated 
to have a significant role in development. In mice, SRG3 is essen-
tial to early embryogenesis, as well as having a specific require-
ment for brain development and T-cell differentiation.6 SRG3 
also can be induced by androgen and subsequently transactivate 
AR in the prostate.18 Reduction of SRG3 leads to a significant 
inhibition of GC-induced apoptosis.19 The role of alterations in 
BAF155 expression/function in tumorigenesis remains unclear. 
Its loss could contribute to tumor development due to its loca-
tion in region of chromosome band 3p21.31, that includes other 
suspected tumor suppressor genes, such as SEM3B and FUS1.20,21 
However, other studies have found increased expression of 
BAF155 mRNA in cervical intraepithelial neoplasia (CIN), pros-
tate cancer and colorectal cancer.22-25
This study sheds light on the potential tumor-suppressor 
functions of BAF155 by characterizing 2 human tumor cell lines 
that lack BAF155 expression. Our studies demonstrate that re-
expression of exogenous full length BAF155 induces senescence 
in these cell lines. In contrast, exogenous expression of BAF155 
Figure 1. SKOV3 and SNUC2B cell lines lack BAF155 protein but not BAF155 mRNA. (A) Thirty μg of total cellular protein from each cell lines was sepa-
rated by SDS-PAGE and characterized for expression of the indicated proteins by protein gel blot analysis. The actin-related BAF53 protein served as 
the loading control. (B) Thirty micrograms of mRNA of each cell line was analyzed by RNA gel blot and probed with a BAF155 cDNA probe. 18S and 28S 
bands served as loading controls. (C) Both cell lines lacking BAF155 protein expression were analyzed by QT-PCR expression for BRG1, SNF5, BAF155 
and BAF170. The number of ΔCt cycles at 3 different concentrations of cDNA were assessed for each gene and normalized to the corresponding num-
ber for BRG1 amplification. The results represent triplicate results from 2 independent experiments.
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protein poly-ubiquitination significantly increased during the 
same time period (Fig. 3). Treatment with an alternative protea-
some inhibitor, MG132, gave similar results (data not shown).
BAF155-induced growth inhibition of carcinoma cells via 
senescence. We next assessed the effects on cell growth after re-
expression of BAF155 in the cell lines lacking endogenous expres-
sion. We used expression vectors that coded for either a full-length 
protein or one with a 332 aminoacid deletion of the c-terminus-
BAF155Δ2 (Fig. 4). This size of this deletion approximates the 
one found in the SKOV3 cell line (Fig. 2). We have previously 
shown that the c-terminal deletion abrogates BAF155’s ability to 
regulate the stability of another complex member, BAF57 (Chen, 
2005).
We assessed the effects of full-length or truncated BAF155 
protein expression upon long-term proliferation by a colony-
forming assay. Colony forming assays showed a marked reduc-
tion in colony forming ability in BAF155 null cells after wild type 
BAF155 re-expression, but not when transfected with mutant 
BAF155 (Fig. 4). No effect on colony forming ability was seen in 
HeLa cells after transfection with either BAF155 expression vec-
tor. In contrast, the BAF155Δ2 truncation mutant was severely 
abrogated for its growth suppressive activity (Fig. 4). These 
results support the notion that if the deleted form of BAF155 is 
expressed in the SKOV3 cell line, its normal functions would be 
impaired.
To determine if the inhibition of growth was due to a senes-
cent or apoptotic response, we investigated typical markers of 
each of these events in both cell lines at several time points fol-
lowing re-expression of BAF155. We did not observe an increase 
in DNA fragmentation, characteristic of early to mid apoptosis, 
by TUNEL staining at 2 d following BAF155 expression (Table 
4). In contrast, approximately 11% of the BAF155-deficient cell 
lines expressed the senescence marker, β-galactosidase by 10 d, 
a 10X increase over the vector control (Table 4). These results 
appear similar to those observed upon re-expression of BRG1 in 
BRG1/BRM-deficient human tumor cell lines.15,28-31
Cells lacking BAF155 expression retains the ability to sup-
port Rb-mediated cell cycle arrest. We then determined whether 
the cell lines could undergo RB-mediated cell cycle arrest in 
the absence of BAF155 protein. Upon infection with p16INK4A 
previously reported, the expression of other complex members 
appeared reduced in the absence of BAF155 expression (Fig. 
1A).27 We then assessed mRNA levels by RNA gel blot analy-
sis to determine if the cell lines failed to transcribe BAF155. As 
shown in Figure 1B, both cell lines expressed comparable levels 
of BAF155 mRNA to BAF155 positive cell lines. Because of the 
strong homology between BAF155 and BAF170, we confirmed 
these results with real time PCR. We did not observe any reduc-
tion in BAF155 or BAF170 expression in comparison to expres-
sion of the core ATPase, BRG1, by this method (Fig. 1C).
Ovarian carcinoma cell line SKOV3 expresses a mutation 
in the BAF155 gene. To determine the reason for the lack of 
BAF155 protein expression in the two deficient cell lines, we 
sequenced the BAF155 mRNA to search for mutations. In the 
SKOV3 cell line, we found a 4 base pair deletion in exon 24 lead-
ing to a stop codon at 2,566 bp (Fig. 2). This mutation would 
yield a truncated protein of 855 aminoacids, instead of the full-
length protein of 1,105 aminoacids. The loss of the last 250 ami-
noacids would remove the leucine zipper and proline-glutamine 
rich domains as well as the antibody binding site used in the 
protein gel blot in Figure 1A. Although we did not observe a 
BAF155 product of any size on western gels, we cannot rule 
out production of a truncated protein by the SKOV3 cell line. 
Genomic sequencing of exon 24 revealed the presence of both 
mutant and wild-type alleles. Therefore, silencing of the wild-
type allele had apparently occurred in this cell line. The primary 
sequence of SNUC2B has not yielded a mutation. We are cur-
rently sequencing the untranslated regions of mRNA to look for 
potential abnormalities in protein translation signals.
Loss of BAF155 in the SNUC2B cell line is not due to protea-
some degradation. We next determined if the absence of BAF155 
protein resulted from increased protein degradation. Cells were 
treated with lactacystin, a proteasome inhibitor, for up to 36 h, 
harvested for protein and analyzed by protein gel blot for BAF155 
expression. In order to assess the inhibition of proteasome degra-
dation, we assessed expression of c-JUN, a protein with a rapid 
degradation rate, as well as poly-ubiquitination of proteins using 
an anti-ubiquitin antibody. As shown in Figure 3, after lactacys-
tin treatment, we did not observe re-expression of the BAF155 
protein in the SNUC2B cell line. In contrast, both c-JUN and 
Figure 2. SKOV3 contains a truncating mutation in the BAF155 gene. Sequence of exon 24 of SKOV3 ovarian carcinoma cell line lacking protein expres-
sion. Individual exons were amplified by PCR, purified and sent to UNC-CH Genome Analysis Facility for analysis. This 4 bp deletion mutation leads to a 
stop codon at 2,666–2,669, yielding an 855AA truncated BAF155 protein. Result was confirmed three times.
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encoding adenovirus, both cell lines demonstrated a significant 
inhibition in BrdU incorporation (Fig. 5A). Furthermore, each 
cell line showed decreased expression of the cell cycle protein 
CCNA (cyclin A) as well as the expected expression of the trans-
fected p16INK4A (Fig. 5B). These data indicate that the SWI/SNF 
complex can efficiently regulate RB mediated cell cycle arrest 
even in the absence of full length BAF155.
Discussion
The previously conceived notion of cancer etiology being nature 
OR nurture has been replaced with the knowledge that carcino-
genesis often includes both genetic and environmental factors. 
This paradigm becomes more obvious as the field of epigenetics 
comes into focus to reveal its importance in cancer develop-
ment and progression. Many diverse complexes, including the 
SWI/SNF complex, carry out the chromatin remodeling arm of 
epigenetic modification. In yeast, a fully-functional SWI/SNF 
complex includes all complex members32,33 and the loss of any 
component causes subtle changes in complex activities. In mam-
malian cells, the SWI/SNF complex associates with and possibly 
regulates cell cycle control genes including pRB,17,28 BRCA1,12 
p21CIP1/WAF1,15,16,34 p16INK4A 9 and Cyclins E and A.17,29 A loss of 
any SWI/SNF member could contribute to the tumorigenicity 
of a cell given these connections to Rb function as well as other 
cell cycle regulators. This is indeed true for SWI/SNF complex 
member SNF5/INI1, as loss of SNF5 activity appears to abrogate 
the RB signaling pathway through a block in p16INK4A or p21CIP1/
WAF1 induction or increased expression of cyclin D1.9
In this report, we have revealed a role for another core SWI/
SNF member, BAF155, in cell cycle checkpoint control and 
likely tumor suppression, via its leucine-zipper domain. We show 
expression of exogenous BAF155 in carcinoma cells 
lacking BAF155 consistently produces replicative 
senescence. This effect was also seen with low lev-
els of BAF155 expression in the stable clones two 
weeks post-transfection. This low level of exogenous 
BAF155 was sufficient to cause substantial inhibi-
tion of colony forming ability. These data indicate a 
vital (direct or indirect) role for BAF155 in the con-
trol of carcinoma cells SKOV3 and SNUC2B. The 
leucine zipper or proline/glutamine rich domain of 
BAF155 would seem to control this effect, as trans-
fection with the Δ2 mutant lacking these domains 
Figure 3. BAF155 protein is not degraded by the ubiquitin-proteasome 
pathway in the SNUC2B cell line lacking BAF155 expression. Increased 
time after lactacystin treatment inhibits proteasome degradation as 
demonstrated by the increased poly-ubiquination of protein and the 
increase of c-jun protein. Mock treatment with DMSO revealed the ac-
cumulation is due specifically to the lactacystin treatment. The SUM149 
breast tumor cell line serves as a positive control for BAF155 protein 
expression.
Figure 4. Re-expression of BAF155 suppresses growth 
of BAF155-deficient cell lines. (A) Schematic of BAF155 
expression vector contents used for re-expression stud-
ies in this and subsequent figures. Note the striped boxes 
indicate the identifiable tag for each insert. The delta-2 
mutant BAF155 also has added a nuclear localization 
signal. (B) Results of the 14 d colony forming assay. Cells 
were carried under selection for 12 d beginning 2 d 
post-transfection. Bar values were calculated by a ratio of 
stained colonies from the BAF155 transfected cells pres-
ent at day 14 to the colonies of vector control transfected 
cells for each cell line.
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one core member above does induce growth arrest via senescence, 
a key characteristic of many tumor suppressors. This implies 
SWI/SNF complex may participate in more than one pathway 
to halt cell cycle progression. Additional mutational or inactiva-
tion studies are required to determine the pathways SNF5 and 
BAF155 operate through to halt tumor cell progression.
The lack of protein expression in SNUC2B without a muta-
tion in the primary sequence or apparent degradation by the 
proteasome can be reconciled in a number of ways. The region 
of chromosome 3 where BAF155 is found is home to a cluster 
of suspected tumor suppressor genes. It is of note that somatic 
mutations have rarely been found in genes in the 3p21 region 
(only 5 of >200 primary human cancers) although many tumors 
show inactivation of these genes.36-38 Further, the non-expressed 
but non-mutated 3p21 genes are found inactivated by other 
inactivated its ability to suppress growth in the two carcinoma 
cell lines.
BAF155 is the third core member of the SWI/SNF complex 
to demonstrate tumor suppressive capabilities related to cell cycle 
control. Table 5 summarizes the tumor suppressive capabilities 
of the core members of the SWI/SNF complex. All core mem-
bers are required for the basic task of remodeling nucleosomes, 
but the necessity for their presence in specific tumor suppressive 
functions of the complex varies. It appears that RB-mediated cell 
cycle arrest requires only one of the catalytic core subunits, BRG1 
or BRM. The specific functions served by SNF5 and BAF155 
seem dispensable for this particular tumor suppressive activity 
of the SWI/SNF complex. In the case of BAF155 loss, increased 
expression of its highly related paralog BAF170 may substitute as 
recently demonstrated by Yan et al. However, re-expression of any 
Figure 5. BAF155-deficient cell lines retain Rb-mediated growth sensitivity. (A) Thirty six hours after infection with adenoviruses expressing either GFP 
or p16INK4A, cells were analyzed for incorporation of BrdU and graphed as a ratio of BrdU positive cells in the GFP control cells for each cell line. The TSU 
Pr-1 prostatic carcinoma cell line served as a positive control for p16INK4A growth inhibition and the BRG1/BRM-deficient SW13 adrenal carcinoma cell 
line served as a p16INK4A non-responsive control. (B) SKOV3 and SNUC2B cells were infected with GFP or p16INK4A encoding adenoviruses. Protein gel blot 
run from protein extracted 36 h later.
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BAF170. The BAF155 and BAF170 proteins share significant 
sequence and domain homology. Therefore, BAF170 may take 
over as the scaffold in these cells, allowing the complex to form. 
Clearly, other functions specific to BAF155 must exist whose 
loss leads to a cancerous phenotype that we see reversed upon 
exogenous BAF155 expression (Figs. 3 and 4). While some SWI/
SNF members appear vital to development (e.g., BRG1, SNF5 
and BAF155), others remain dispensable (BRM) as demonstrated 
by the embryonic lethality of mice null for those subunits.4-8,46 
Many of the studies performed to support the scaffold theory 
were done in immature cells-MEFs, developing thymocytes, or 
actively growing, transformed, immortalized cancer cell lines.40,41 
It is possible BAF155 serves the purpose of scaffolding during 
development but may share this function with BAF170 upon 
cellular differentiation. Further characterization of BAF155 and 
BAF170 expression in developing or differentiating cells (such 
as the MEFs or developing thymocytes previously tested) would 
address these issues.
In conclusion, we submit an additional SWI/SNF core sub-
unit, BAF155/SMARCC1 as a likely tumor suppressor gene due 
to its loss in two carcinoma cancer cell lines including a hemi-
zygous mutation, its genomic location in the tumor suppressor 
cluster region of chromosome 3p21 and because of its ability to 
cause a replicative senescence in deficient cancer cell lines upon 
its re-expression. As mentioned earlier, BAF155 may be targeted 
as part of a tumor suppressor gene cluster on 3p21 to be epi-
genetically silenced, thereby affecting all SWI/SNF regulated 
genes, which are often cell cycle related. The next step in the 
determination of potential effectors of BAF155 loss in cancer 
cells is exploration of epigenetic silencing mechanisms such as 
promoter hypermethylation, aberrant acetylation patterns and 
myristoylation in normal developing cell lines such as MEFs or 
developing thymocytes known to have highly regulated BAF155, 
as well as in differentiated cells, cancer cells and “normal” cells 
such as normal human fibroblasts. Further studies into the inac-
tivation of SWI/SNF complex members in the development of 
human cancer should provide important new targets for treat-
ment intervention, potential biomarkers for early detection and 
novel insights into the role of altered nucleosome positioning in 
gene silencing.
Materials and Methods
Cell lines. All cell lines were grown at 37°C in a 5% CO
2
 incuba-
tor with RPMI 1640 medium base supplemented with 10% FBS 
with the exception of SNUC2B which was grown in 20% FBS. 
Cell lines listed were originally acquired from ATCC except the 
HeLa derivative D98oR, that was originally isolated by Weissman 
and Stanbridge.47 All cell lines were tested for mycoplasma and 
found to be negative.
DNA transfection. Transfection of expression vectors were 
performed by the Lipofectamine 2000 (Invitrogen) or Effectine 
(Qiagen) method according to the manufacturer’s instructions. 
Expression vectors are listed in Table 1. Twenty-four hours after 
transfection, the cells were equally divided into eight 100 mm 
dishes. After an additional 24 h, growth medium containing 
epigenetic mechanisms, such as chromosome instability, aneu-
ploidy, promoter methylation, haploinsufficiency, altered RNA 
splicing, or defects in transcriptional, translational or post-trans-
lational processes. Some are inactivated by rather exotic epigen-
etic means. For example, the FUS1 gene may express mRNA 
with no apparent mutations without any protein by protein gel 
blot, IHC or microtissue array, similar to BAF155 in SNUC2B. 
Also, like so many 3p21 genes, FUS1 is a likely tumor suppressor 
gene, shown to be lost in >50% of lung cancers cell lines tested. 
It was eventually discovered that wild type FUS1 could be found 
as an N-myristoylated protein. Significant loss of expression or a 
myristoylation defect of the FUS1 protein was found in deficient 
lung cancer cell lines.39 A more extensive proteasome-degradation 
inhibitor may be necessary to ensure that degradation is not the 
cause of BAF155 protein absence in SNUC2B. Another possibil-
ity is a mutation in the large non-coding exon accounting for 
the last 1,500 bp of the BAF155 mRNA. Mutations within this 
region could result in significant changes in the tertiary structure 
of the mRNA leading to inefficient protein translation. We are 
currently determining the sequence of this region to assess this 
prospect.
The importance of SKOV3’s lost leucine-zipper domain in 
BAF155 may be its ability to bind with other SWI/SNF com-
plex members. It is known that leucine zipper domains in general 
allow the proteins possessing them to dimerize, with themselves 
(homodimerize) or with other proteins possessing a leucine 
zipper domain (heterodimerize). This has been suggested for 
BAF155 and BAF170. Chen and Archer recently demonstrated 
another function for BAF155’s leucine zipper domain.40 This 
domain was shown to be necessary for BAF155’s interaction with 
BAF57, stabilizing BAF57 in the cell. In fact, similar functions 
have been shown for several of BAF155’s domains. The SANT 
domain of BAF155 has been shown to be necessary for BRG1 
binding and stabilization41 and BRM binding.42 The SWIRM 
domain of BAF155 was required for BAF60a and SNF5 binding 
and stabilization.41 Therefore, it has been proposed BAF155 is the 
scaffolding protein for the SWI/SNF complex, linking BRG1, 
and the therefore the remodeling capabilities of the complex, to 
the other subunits which interact with transcription factors or 
other targeting molecules. Our data would not seem to totally 
support this notion, as we observe the presence of the other SWI/
SNF members in cells in the absence of detectable expression 
of BAF155 protein (Fig. 1A). However, we also note reduced 
levels of BAF57 and BAF47 (SNF5) proteins in the BAF155-
deficient cell lines compared with the BAF53 protein loading 
control. Furthermore, the recent reports demonstrating muta-
tions in the SWI/SNF complex components PBRM1 (BAF180) 
in renal cell carcinoma and especially ARID1A (BAF250A) in an 
aggressive form of ovarian carcinoma offer another mechanism 
whereby BAF155 loss could lower stability of these tumor sup-
pressor proteins.43-45 Thus, our results appear consistent with a 
role for BAF155 in complex stabilization. A determination of the 
region(s) of BAF155 required for growth suppression and cellular 
senescence will provide further insight into this mechanism.
Another confounding issue not addressed in previous studies 
comes from the existence of the closely related SWI3 homolog, 
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exons according to the primers listed in Table 3. BAF155 sequenc-
ing samples were submitted to UNC-CH sequencing facility 
according to their instructions.
Protein stability. Cells were treated with Lactacystin 
(Calbiochem #426100) or MG132 (Sigma #C2211), dissolved in 
dimethysulfoxide (DMSO), for the times indicated in the fig-
ure. Total cellular proteins were then harvested in 8 M urea and 
assessed for specific protein expression by protein gel blot analy-
ses as outlined above.
RNA gel blotting. Expression of BAF155 mRNA was deter-
mined by standard RNA gel blot protocol. Total cellular RNA 
was extracted using the Qiagen RNeasy kit. Fifteen micrograms 
of total RNA were run on 1% agarose/formaldehyde gels and 
were gravity transferred to positively charged nylon membranes. 
The membranes were stained for ribosomal 28s proteins for equal 
loading. BAF155 probes were 32P-radiolabeled by random primer 
extension, hybridized to membranes and subsequently rinsed to 
remove nonspecific radioactivity. Hybridization bands were visu-
alized by autoradiography.
Real-time PCR. Total RNA was isolated from each cell 
line using the Qiagen RNA extract kit (Qiagen, Valencia, 
CA) according to manufacturer’s protocol and analyzed by the 
TaqMan (Applied Biosystems, Foster City, CA) quantitative 
real-time reverse-transcription PCR using β-actin as a reference 
gene in each reaction. Primers used were as follows: BAF155: 
CAC CCC AGC CAG GTC AGA T (forward) and TGC AAC 
AGT GGG AAT CAT GC (reverse); BAF170: GAG AAG CAC 
TGG AGT ATC AGA (forward) and ATC TCC GCA TAC 
TTC AGC TG (reverse); BRG1: GAT AAA GGA GCG CAT 
TCG CA (forward) and TTC TGG CAC AGG AGC ATG AC 
(reverse); and SNF5: CAG AAG ACC TAC GCC TTC AG 
(forward) and GTC CGC ATC GCC CGT GTT (reverse). 
The probes used were CAG GCC CAG GTT CCA TGA TGC 
CCG (BAF155), CAG CAG CTC CTG GCC GAC AGA CAA 
G (BAF170), CAA GTA CCG CAG CCT CAA CGA CCT 
600 μg/ml neomycin was added to the dishes. The cells were 
allowed to grow for 14 d. The dishes were then fixed with etha-
nol, stained with Coomassie Blue and assessed for colony num-
ber by visual inspection. The data represent the results of three 
independent experiments.
Protein gel blots. For protein preparation, subconfluent cells 
were removed by trypsinization, washed once in PBS and total 
proteins were extracted using 8 mol/L urea as described previ-
ously in reference 34. Protein concentration was quantified by 
the Bio-Rad protein assay (Bio-Rad Labs, Hercules, CA) per 
manufacturer’s instructions. Proteins (30 μg) were separated 
by electrophoresis on 4–20% or 7.5% SDS-polyacrylamide 
gels (Cambrex, Rockland, ME) and electrotransferred onto 
Immobilon-P membranes (Millipore, Billerica, MA) according 
to the manufactures’ instructions for Biomax ML film (Kodak, 
Cedex, France). All antibodies were used per manufacturer’s 
instructions unless otherwise specified in the figure legend. The 
source of antibodies used for protein gel blot and immunohisto-
chemistry is outlined in Table 2.
DNA extraction from cell lines for sequencing. Genomic 
DNA was extracted using the Qiagen DNeasy kit per manufac-
turer’s instructions. For cDNA, mRNA was first extracted with 
the Qiagen RNeasy kit and then reverse transcribed using the 
Qiagen RT-MMLV kit according the manufacturer’s instructions.
Sequencing. Sequencing primers were designed according to 
the NCBI database sequence of BAF155 to amplify individual 
Table 1. Source and description of expression vectors
Plasmid Content of plasmid Source
pcDNA3/BAF155-V5













pCMV Empty vector control 40
Table 2. Antibodies used for studies
Antibody Brief description Source
BAF155 (H-76) Rabbit polyclonal, (AA 889–913) Santa Cruz sc-10756
β-ACTIN Rabbit polyclonal, Sigma A2066
BRG1 (G-7) Mouse monoclonal Santa Cruz sc-17796
BRM Rabbit polyclonal Abcam ab15597
SNF5 Mouse monoclonal Transduction Labs, 612110
BAF57 Rabbit polyclonal Gift of Karen Knudsen, Thomas Jefferson Medical School
BAF170 Rabbit polyclonal Gift of W. Wang, National Institute of Aging.
C-JUN Rabbit polyclonal Oncogene Science PC07
UBIQUITIN Mouse monoclonal Santa Cruz sc-8017
C-MYC (9E10) Mouse monoclonal Santa Cruz sc-40
V5 Mouse monoclonal Invitrogen R961-25
CCNA Rabbit polyclonal SCBT H-432
p16INK4A Mouse monoclonal BD PharMingen G175–1239
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following transfection with plasmids, at times post-transfection 
as indicated in each figure. At least 200 cells were counted in 
each of at least three independent experiments for each condition.
Senescence detection via β-galactasidase. Senescence-
associated β-galactosidase was performed as previously described 
in reference 48, with modifications of Kramer et al. Briefly cells 
A (BRG1) and ACC CTC TGC CCA CAG TGG AGA TTG 
(SNF5).
Apoptosis detection—TUNEL assay. Apoptosis via DNA 
fragmentation was measured using the “In Situ Cell Death 
Detection Kit, TMR red” from Roche (catalog # 12 156 792 
910). The kit was used according to manufacturer’s instructions 
Table 3. Primers used for determining BAF155 sequence in cDNA and genomic DNA
cDNA Primer# Primer sequence (forward) Primer sequence (reverse)
1 ACG ACG GGC TGC GAC GAT G CAC CGA ATC CAG CTG GGG AC
2 TTG GTG CAG AAC AAT TGT TTG ACC CAA GAA TGT GAC ATA AGG CGC
3F GCC AGT CAG AAG TCC AGA AAG AAG
7R GAG TGC TGG TGT GCC TGT TG
9R1 CGT GGA GGT TCC CTG CAT C
16 CAA TGC CAG GAA ACA TCT TAG GA TCC TAA GAT GTT TCC TGG CAT TG
122 CGC AGG CCT AGC TGT TTA TC TCG ATA AAC AGC TAG GCC TGC G
290 GTG CAG CTT CTT CAG TTC C TTC CTG GAA CTG AAG AAG CTG CAC C
425F CAA GTA TAA AAA TGA ACA GGG ATG G
545F ATC TCG AAT GGA TCG TAA TG
660F CAC ATT TAC CCA TAT TCT TCC TCA C
744R AAT GCA CTA ACA CTT GCT TCT CTT T
859F TGG ACA CTG ATA TTT TCA ATG AAT G
1001R TGC TTT TCT ATC TCT TCT TTC TGG A
1167F CCA ACA CCT GTA CCC AAT ATA GAA G
1191R TCT TTC TTT AGG TTC ACA TTT TTG G
1538F GTA TCG TCT AAA CCC CCA AGA GTA T
1562R ATA CTC TTG GGG GTT TAG ACG ATA C
1812F CAG ATG CTA AAT TTT CCT GAG AAA A
1866R AGT AAA TGT CAG TAC GGA GAC CAA A
2496 GAA AAG GAA CAG GAT AGT GAA GTG A TCA CTT CAC TAT CCT GTT CCT TTT C
2822R GGA AAC TAT CAT GGA CAG AGA GAA A
2833R TCT AGA GCT TCT TTC TCT CTG TCC A
3123R CTG CAA CAG TGG GAA TCA TG
3340R CTG CAT CTT CCA GGC TAA GG
Exon Forward Primer Reverse Primer
Exon 1 TTG CAT ATT CGT GGT TCT AAA TTC GAG GCC AGC TGC CGC CT
Exon 16 GCA CAT GAA GTT GAT TCT TTA G CAA CCC CTA AAT GGC ATA AC
Exon17 AGA GGC TAA CTC AGC CAT TT GCC ATT TGT TAC TAT CCA GTC
Exon 18 CTG AGC TCC ATC TTC AGC AT ACT AAG ATG TGC TGG ATT GC
Exon 19 CTG AGC TCC ATC TTC AGC AT GGT GAC ACA CAG CGA GAC C
Exon 20 TCT TGT TAC CTG ACA TGA AAG C ATG AAT GTA ACG GCT GGT AA
Exon 21 AAG TTA GAT TGC TGT TCC AT TAT ACT GAT CAT TGT ACT CAC T
Exon 22 CAG ACA CTC TCA CAG CTG TA GGT CTG AAA GGC ATG CTA TC
Exon 23 CGA GCT GTT CTC TAC AAG TCA C AAG TGT AGC CAC CAG CAT TA
Exon 24 GAG AGT GGG CAC GCT AGT A CAA TAC GAG CAT TCA TGC CT
Exon 25 AGC TTG AAT GAT CTT GTA CC TGG AAA AGT GAC CAA GGT T
Exon 26 CTG GTG TCA TTT CTT CCA CT CCC TAA ATC TCA CAT GCC TAC
Exon 27 GTT GAT CCC TTT CTT ACA CCC AAC GGA CCC TGA GATA ATG C
Exon 28 TCC AGC AAT AAC GAG TTA CTC CAC GGC TTG GAG CTG TGA G
1452 Epigenetics Volume 6 Issue 12
Acknowledgments
This work was supported, in part, by R01CA91048 and 
R01CA138841 (B.E.W.), by the Intramural Research Program of 
the National Institute on Aging (grant AG000650-10), National 
Institutes of Health (W.W.), by the Intramural Research Program 
of the National Institute of Environmental Health Sciences 
(Z01 ES071006-11), National Institutes of Health (T.K.A.) 
and by R01CA127387 (E.S.K.). Dr. Delbove was supported, in 
part, by a training grant from the National Institutes of Health 
T32ES007017.
were washed with PBS, fixed for 3 min with 3% formaldehyde/
PBS, washed three times with PBS, and incubated overnight in 
a 37°C incubator in SA-β-gal solution 5 mM potassium fer-
rocyanide, 5 mM potassium ferricyanide, 2 mM MgCl
2
 and 1 
mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-Gal in 
PBS). Plates were visualized with bright field microscopy on a 
Zeiss 1M 35 microscope. Results are representative of duplicate 
experiments.
Disclosure of Potential Conflicts of Interest
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Table 4. Effect of BAF155 reexpression on replicative senescence and apoptosis
Cell Line Transfection Average apoptosis (%) (48 h) Average βGal positive (%) (10 d)
Mean Std. Dev. Mean Std. Dev.
SNUC2B vector 0.06 0.0032 1.4 0.8
BAF155 0.07 0.0075 11.0 0.1
BAF155-Δ2 0.06 0.0074 - -
β-Gal - - 20.5 0.2
SKOV3 vector 0.03 0.0015 1.9 1.4
BAF155 0.04 0.0044 11.0 2.5
BAF155-Δ2 0.04 0.0191 - -
β-Gal - - 22.3 3.8
HeLa vector 0.08 0.0050 1.5 0.7
BAF155 0.08 0.0074 1.5 0.7
BAF155-Δ2 0.08 0.0069 - -
β-Gal - - 20.4 2.3
TUNEL Apoptosis detection. Cells were analyzed 48 h post co-transfection with GFP and one of the following: empty vector control, V5 tagged full 
length BAF155, or myc tagged Δ2 truncation mutant BAF155. A ratio of TUNEL positive (broken DNA ends = apoptosing) cells to GFP positive cells (pre-
sumed to express BAF155 as well) were averaged and normalized to empty vector control cell.
Table 5. Comparison of tumor suppressor properties of SWI/SNF complex core components
SWI/SNF core subunit Required for RB-mediated arrest? Can cause growth arrest? Induces senescence? Involved in apoptotic signaling?
BRG1/BRM yes yes yes no
SNF5 no yes yes no
BAF155 no yes yes no
Summary of the tumor suppressor capabilities of SWI/SNF core members. Data compiled from this study and previous studies as discussed in the text.
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